Zhe Zheng1,2, Haojie Li1,2, Sheng Liu1,2, Ge Gao1,2, Chunyu Yu1,2, Hengqiang Lin1,2, Ying Meng1,2. 1. National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 2. Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Abstract
OBJECTIVES: Thoracoscopic epicardial ablation with a limited lesion set led to suboptimal results for advanced paroxysmal atrial fibrillation (AF) or persistent AF. Whether additional right atrial lesions improve the result is unclear. METHODS: We conducted a retrospective study involving 80 consecutive patients with paroxysmal or persistent AF, left atrial (LA) dilation (LA diameter >40 mm) and failed prior interventional ablation (40 patients, 50%) who underwent thoracoscopic epicardial ablation with box lesions (36 patients) or bi-atrial (BA) lesion (44 patients) in our institution. Freedom from atrial tachyarrhythmias after the procedures was compared between the box lesion group and BA lesion group. RESULTS: Baseline differences included more patients with persistent AF (86.4% vs 47.2%) and larger left atrium [48.00 (44.00-50.75) vs 42.00 (41.25-44.00) mm] in the BA lesion group. There was no difference in procedural complications between the 2 groups. After a mean follow-up of 32 months, the freedom from atrial tachyarrhythmias off antiarrhythmic drugs at 6, 12 and 24 months was 77.2%, 77.2% and 77.2% in the BA lesion group and 69.4%, 50.0% and 40.6% in the box lesion group, respectively (P = 0.006). After adjustment for sex, age, body mass index, LA diameter, AF type, history of AF, and previous interventional ablation, BA lesion was an independent predictor of lower atrial tachyarrhythmia recurrence (hazard ratio 0.447, 95% confidential interval 0.208-0.963; P = 0.040). CONCLUSIONS: Compared with the box lesion set, thoracoscopic epicardial ablation with BA lesion sets might provide better freedom from atrial tachyarrhythmias for paroxysmal or persistent AF with LA dilation. Randomized control trials are warranted to confirm the benefit of BA lesion sets in these patients.
OBJECTIVES: Thoracoscopic epicardial ablation with a limited lesion set led to suboptimal results for advanced paroxysmal atrial fibrillation (AF) or persistent AF. Whether additional right atrial lesions improve the result is unclear. METHODS: We conducted a retrospective study involving 80 consecutive patients with paroxysmal or persistent AF, left atrial (LA) dilation (LA diameter >40 mm) and failed prior interventional ablation (40 patients, 50%) who underwent thoracoscopic epicardial ablation with box lesions (36 patients) or bi-atrial (BA) lesion (44 patients) in our institution. Freedom from atrial tachyarrhythmias after the procedures was compared between the box lesion group and BA lesion group. RESULTS: Baseline differences included more patients with persistent AF (86.4% vs 47.2%) and larger left atrium [48.00 (44.00-50.75) vs 42.00 (41.25-44.00) mm] in the BA lesion group. There was no difference in procedural complications between the 2 groups. After a mean follow-up of 32 months, the freedom from atrial tachyarrhythmias off antiarrhythmic drugs at 6, 12 and 24 months was 77.2%, 77.2% and 77.2% in the BA lesion group and 69.4%, 50.0% and 40.6% in the box lesion group, respectively (P = 0.006). After adjustment for sex, age, body mass index, LA diameter, AF type, history of AF, and previous interventional ablation, BA lesion was an independent predictor of lower atrial tachyarrhythmia recurrence (hazard ratio 0.447, 95% confidential interval 0.208-0.963; P = 0.040). CONCLUSIONS: Compared with the box lesion set, thoracoscopic epicardial ablation with BA lesion sets might provide better freedom from atrial tachyarrhythmias for paroxysmal or persistent AF with LA dilation. Randomized control trials are warranted to confirm the benefit of BA lesion sets in these patients.
Authors: Sébastien P J Krul; Antoine H G Driessen; Aeilko H Zwinderman; Wim J van Boven; Arthur A M Wilde; Jacques M T de Bakker; Joris R de Groot Journal: Int J Cardiol Date: 2011-11-09 Impact factor: 4.164
Authors: Brian J Hansen; Jichao Zhao; Ning Li; Alexander Zolotarev; Stanislav Zakharkin; Yufeng Wang; Josh Atwal; Anuradha Kalyanasundaram; Suhaib H Abudulwahed; Katelynn M Helfrich; Anna Bratasz; Kimerly A Powell; Bryan Whitson; Peter J Mohler; Paul M L Janssen; Orlando P Simonetti; John D Hummel; Vadim V Fedorov Journal: JACC Clin Electrophysiol Date: 2018-11-01
Authors: James L Cox; Andrei Churyla; S Chris Malaisrie; Duc Thinh Pham; Jane Kruse; Olga N Kislitsina; Patrick M McCarthy Journal: Ann Thorac Surg Date: 2018-08-14 Impact factor: 4.330
Authors: Vinay Badhwar; J Scott Rankin; Niv Ad; Maria Grau-Sepulveda; Ralph J Damiano; A Marc Gillinov; Patrick M McCarthy; Vinod H Thourani; Rakesh M Suri; Jeffrey P Jacobs; James L Cox Journal: Ann Thorac Surg Date: 2017-06-29 Impact factor: 4.330
Authors: John M Miller; Vikas Kalra; Mithilesh K Das; Rahul Jain; Jason B Garlie; Jordan A Brewster; Gopi Dandamudi Journal: J Am Coll Cardiol Date: 2017-03-14 Impact factor: 24.094
Authors: Lucas V A Boersma; Manuel Castella; Wimjan van Boven; Antonio Berruezo; Alaaddin Yilmaz; Mercedes Nadal; Elena Sandoval; Naiara Calvo; Josep Brugada; Johannes Kelder; Maurits Wijffels; Lluís Mont Journal: Circulation Date: 2011-11-14 Impact factor: 29.690
Authors: Brian J Hansen; Jichao Zhao; Thomas A Csepe; Brandon T Moore; Ning Li; Laura A Jayne; Anuradha Kalyanasundaram; Praise Lim; Anna Bratasz; Kimerly A Powell; Orlando P Simonetti; Robert S D Higgins; Ahmet Kilic; Peter J Mohler; Paul M L Janssen; Raul Weiss; John D Hummel; Vadim V Fedorov Journal: Eur Heart J Date: 2015-06-08 Impact factor: 29.983
Authors: Krzysztof Bartuś; Andy C Kiser; Jacek Majewski; Bogusław Kapelak; Janusz Konstanty-Kalandyk; Jacek Lelakowski; Jacek Bednarek; Stanisław Bartuś; Karol Wierzbicki; Robert Sobczyński; Jerzy Sadowski Journal: Pol Arch Med Wewn Date: 2012-04-11